This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garde, A. Articles by Ostman, J. Search for Related Content PubMed PubMed Citation Articles by Garde, A. Articles by Ostman, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID Medline Plus Health Information Transient Ischemic Attack

Stroke, Vol 14, 677-681, Copyright © 1983 by American Heart Association

ARTICLES

Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation

A Garde, K Samuelsson, H Fahlgren, E Hedberg, LG Hjerne and J Ostman

Treatment with an anticoagulant (AC) or acetylsalicylic acid (ASA), chosen at random, was given to 241 patients with symptoms of carotid transient attacks of ischemia, some of whom recovered completely within 24 hours (TIA) while the others had slight residual symptoms (TIA-IR). Cerebral infarction was recorded in 4 patients in each of these treatment groups during a mean follow-up period of 20 months. The incidences of TIA and TIA-IR were also similar in the two groups. Severe hemorrhage occurred more often in the AC group, whereas other side reactions, including gastrointestinal disorders, were more common in the ASA group. Recurrent cerebral ischemic events were significantly more common among the patients that had had greater than or equal to 2 TIAs in the 14 days immediately preceding randomization, and in those with a history of CVS symptoms more than 14 days before randomization, or those with a carotid bruits. In the group experiencing greater than or equal to 2 TIAs in the 14 days prior to randomization the incidence of recurrent cerebral ischemic events was the same for the two types of treatment.

This article has been cited by other articles:

				M. J. O'Donnell, G. J. Hankey, and J. W. Eikelboom Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review Stroke, May 1, 2008; 39(5): 1638 - 1646. [Abstract] [Full Text] [PDF]

				M. E Schachter, H. A Tran, and S. S Anand Oral anticoagulants and non-cardioembolic stroke prevention Vascular Medicine, February 1, 2008; 13(1): 55 - 62. [Abstract] [PDF]

				M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, and S. Schulman Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 287S - 310S. [Abstract] [Full Text] [PDF]

				A. Algra, E.L.L.M. De Schryver, J. van Gijn, L.J. Kappelle, and P.J. Koudstaal Oral Anticoagulants Versus Antiplatelet Therapy for Preventing Further Vascular Events After Transient Ischemic Attack or Minor Stroke of Presumed Arterial Origin Stroke, January 1, 2003; 34(1): 234 - 235. [Full Text] [PDF]

				R. G. Hart, B. S. Boop, and D. C. Anderson Oral Anticoagulants and Intracranial Hemorrhage : Facts and Hypotheses Stroke, August 1, 1995; 26(8): 1471 - 1477. [Abstract] [Full Text]